Background. Chronic abdominal wall pain arising from the myofascial structures is termed abdominal myofascial pain syndrome and is an important cause of refractory abdominal pain that utilizes significant health care costs. The current literature is vague on its management.
Introduction
Chronic abdominal wall pain (CWAP) is an important but underrecognized cause of nonspecific abdominal pain [1] . In the United Kingdom, it has been estimated that nonspecific abdominal pain costs the economy in excess of £100 million per annum [2] . CWAP arising from the myofascial structures is termed abdominal myofascial pain syndrome (AMPS) and is an important cause of refractory abdominal pain that utilizes significant health care costs [3] [4] [5] . Abdominal myofascial pain syndrome develops as a result of trigger points in the abdominal musculature. Trigger points are spots of exquisite tenderness and hyperirritability in the muscles [6, 7] . Clinical diagnosis is by eliciting the Carnett's sign [4, 5, 8] .
Unlike myofascial pain at other sites, AMPS appears to have two distinct processes involved in its pathogenesis. The abdominal trigger point can develop either as a result of trauma (physical or surgical) or due to the phenomenon of viscero-somatic convergence (VSC) [6, 7, [9] [10] [11] .
Stress and microtrauma to the muscle can cause motor endplate dysfunction with resultant abnormal excessive firing [6, 12, 13] . This mirrors the myofascial pain arising in the trapezius muscle (cervicothoracic myofascial pain). In patients with a history of visceral inflammation, AMPS commonly occurs as a result of VSC [5, 10] .
The current literature fails to define a pathway for the management of abdominal myofascial pain. Management of AMPS includes pharmacological agents, alternative treatments like acupuncture, psychological support, and trigger point injection (TPI) [14] . TPI is usually performed using a landmark (blind) technique [15, 16] . There appears to be a lack of consensus on the agent used in TPI and on the efficacy of trigger point injection [17] .
The author presents the results of a prospective audit of a structured management pathway of AMPS in 120 patients over a three-year period and discusses the pathophysiology of AMPS.
Methods
Adult patients presenting with localized chronic abdominal pain to a single pain physician were included in this audit. Patients with diffuse abdominal pain were not included. The prospective audit spanned three years (2014) (2015) (2016) . The audit was registered with the Clinical Audit Safety and Effectiveness (CASE 7125), University Hospitals of Leicester NHS Trust, UK. The interventions and the questionnaires are standard care for all patients presenting with AMPS. The objective of the audit was to identify an effective and durable treatment for the individual patient and evaluate patient satisfaction with the AMPS management pathway (Figure 1 ).
The patients provided written consent for participation in the audit, for telephone review, for the use of the deidentified data for data analysis and publication in a peer-reviewed journal. All patients diagnosed with AMPS were included in the audit.
In the audit, clinically significant pain relief was defined using the "pain at its worst in the last 24 hours" construct in the Brief Pain Inventory-Short Form (BPI-SF) questionnaire. This 11-point pain intensity numerical rating scale (NRS) has been found to have the strongest relationship with the pain interference scale [18, 19] . Following Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations, a two-point change (30-36%) at three months post-treatment was considered successful intervention [20] . A four-point change (>50) at three months posttreatment and a two-point change (30-36%) at six months post-treatment were considered durable treatment.
Treatment failure was defined as return of "pain at its worst in the last 24 hours" to the baseline at threemonth review following an intervention.
Management Pathway of AMPS
Step 1: Medical management ( Figure 1 ): This included a trial with amitriptyline, pregabalin, and tramadol. A trial with 5% Lidocaine plaster was prescribed in patients Figure 1 Flow chart of the patient progression through the abdominal myofascial pain syndrome management protocol. AMPS ¼ abdominal myofascial pain syndrome; LA ¼ local anesthetic; PRF ¼ pulsed radiofrequency; TPI ¼ trigger point injection; US ¼ ultrasound.
with localized myofascial pain. They were also offered a trial of TENS machine and a course of acupuncture. Patients completed three questionnaires (BPI-SF, Euro Qol 5D-3L, Hospital Anxiety Depression Scale [HADS]) to record baseline scores. Patients were booked for a trigger point injection within eight weeks of presentation. All interventional trigger point treatments were performed under real-time ultrasound guidance. Following each treatment cycle, the patient completed two questionnaires (BPI-SF, Euro Qol 5D) at three months and three questionnaires at six months (BPI-SF, Euro Qol 5D, and HADS). The number of trigger points as well, as the muscles containing the trigger points, was documented. If the six-month post-trigger point treatment HADS revealed significant anxiety and/or depression (score > 9), the patient was referred for medical psychology.
Step 2: Trigger point injection with local anesthetic agent (TPI with LA): Patients underwent a diagnostic TPI with LA within eight weeks of clinical diagnosis to confirm the diagnosis of AMPS.
Step 3: Failure to respond to TPI with LA: Patients who had failed to respond to TPI with LA underwent trigger point injection with mixture of depot steroid and local anesthetic (TPI with steroids).
Step 4: Failure to respond to TPI with steroids: Patients who had failed to respond to TPI with steroids were offered pulsed radiofrequency (PRF) treatment of the trigger point(s).
The patients were followed up over the telephone following each intervention as part of routine care by a specialist nurse in pain management:
• If the pain returned to the baseline within three months, then the patient was booked to receive the next treatment in the pathway.
• If the patient reported greater than 30% relief at three months, then the patient was offered the same treatment or the next treatment in the pathway at six months.
• If the patient reported greater than 50% relief at three months, then the same treatment was repeated at seven to nine months after completion of the two questionnaires.
• Once a durable treatment was identified, it was repeated at seven-to-nine-month intervals.
Data collected included patient satisfaction with the management pathway, complications with the interventional treatments, presence of pain elsewhere in the body, ability to maintain gainful employment, improvement in mood, and quality of life. Women in the reproductive age were not monitored for the phase of menstrual cycle during the treatment period.
The anterior abdominal wall was divided into four quadrants (two upper and two lower). A line drawn across the thoracic T10 dermatome (umbilicus) demarcated the upper and lower dermatomes. The quadratus lumborum muscle was included in the lower quadrant. The number of quadrants involved, the number of trigger points, the muscles involved, and a history of visceral inflammation, if present, were recorded.
In patients with a history of visceral inflammation, certain specific areas were examined to locate the trigger points. They include:
• gastritis, hiatus hernia: both upper quadrants (rectus muscle near the midline); • pancreatitis: left upper quadrant (lateral rectus, oblique, and transversus); • endometriosis, severe dysmenorrhea: both lower quadrants (rectus muscle); • renal inflammation: unilateral lower quadrant (internal oblique, transversus abdominis, and quadratus lumborum muscles); • cystitis: both lower quadrants (rectus muscles);
• bowel inflammation: lower quadrants (rectus muscle);
• biliary: right upper quadrant (rectus, oblique, and transversus).
After the first 30 patients had completed their first interventional treatment (TPI with LA), it was found that the duration of relief was short-lived (less than four weeks) in 100% (30/30) . Subsequently, TPI with LA was not offered to the remaining patients.
Technique
All trigger point injections were performed under real-time ultrasound guidance using an in-plane approach [16] .
• TPI with LA: Each trigger point was treated with 2 mL of 0.5% levobupivacaine.
• TPI with a mixture of steroid and LA: A total of 60 mg of depot methyl prednisolone was used with 0.5% levobupivacaine. Each trigger was treated with 2 mL of the mixture.
• Pulsed radiofrequency treatment: PRF was performed under real-time ultrasound guidance using an in-plane approach. A 20-gauge radiofrequency straight cannula with a 10-mm tip (Neuro Therm, Wilmington, MA, USA) was used. PRF treatment was initiated with an RF generator (Neuro Therm, Wilmington, MA, USA) using the following parameters: voltage output 45 V; 5 Hz frequency; 20-ms pulses in a one-second cycle; impedance range between 150-450 ohm and 42 C plateau temperature. PRF was performed for six minutes. Following PRF, 2-mL of 0.5% levobupivacaine was injected into each trigger point [21] .
Statistical analysis of the results was performed using Stata version 13.1 (Statacorp LC, TX, USA) statistical package for Windows (Microsoft Corp. Redmond, WA, USA). The paired t test was used to compare baseline pain NRS with NRS at each follow-up period (three months, six months). A two-way analysis of variance Niraj was also performed for NRS pain scores in patients who underwent TPI steroids, patients who responded to TPI steroids, and patients who underwent PRF treatment. The paired t test was used for HADS scores at baseline and at six-month follow-up. Differences were considered significant for P < 0.05.
Missing data were imputed using the "last observation carried forward" method.
Results
Over the three-year period, 153 patients were referred to the pain physician with a special interest in chronic abdominal pain. This included both in-patients (admitted to the ward with acute exacerbation) and outpatients referred to the pain clinic. The author has reported on the initial results of in-patient management of AMPS patients [5] .
Active Visceral Inflammation
Fifteen patients were diagnosed with ongoing chronic visceral inflammation-related pain. Clinical examination revealed trigger points, and Carnett's sign was positive. TPI with steroids provided transient relief that lasted six to 72 hours. Subsequent treatment was directed at controlling visceral inflammation and visceral pain management.
Anterior Cutaneous Nerve Entrapment Syndrome
Eighteen patients were diagnosed with anterior cutaneous nerve entrapment syndrome (ACNES). Diagnostic criteria included: Treatment included 5% lidocaine plasters and ultrasound-guided infiltration of a mixture of local anesthetic and depot steroids near the anterior cutaneous nerve at the lateral border of the rectus muscle [22] .
Abdominal Myofascial Pain Syndrome
One hundred and twenty patients were diagnosed with abdominal myofascial pain syndrome and were included in the management pathway for AMPS ( Figure 1 ). The diagnostic criteria for AMPS are:
1. History: constant dull achy pain in the abdomen with intermittent sharp flare-ups referred to the flank, groin, or the leg; aggravated on activity, relieved on curling up, and a past history of visceral inflammation; Table 1 .
Medical Management
Seven patients received significant improvement with initial medical management and were discharged from the service. Data from the first 25 patients revealed that a course of four weekly sessions of acupuncture was found to be ineffective in providing pain relief for more than four weeks. Subsequently, acupuncture was not offered to the remaining patients with AMPS. Five percent lidocaine plasters were effective in a small proportion of patients with localized pain. However, the restriction on their use in the primary care and development of cutaneous allergy limited their use. Amitriptyline and tramadol were found to be effective in conjunction with trigger point treatment. Pregabalin was beneficial in patients with a history of chronic pancreatitis, history of surgery, and in those who scored high on the HADS anxiety scale.
Interventional Management
One hundred and fifteen patients with AMPS who had failed medical management were offered TPI (Figure 2 ). Nine patients refused TPI (needle phobia, patient belief that the source of pain was an underlying visceral disease). One hundred and four patients underwent diagnostic TPI.
Trigger Point Injection with Local Anesthetics
The first 30 patients received trigger point injection with local anesthetics (TPI with LA). All patients reported greater than 50% relief within 30 minutes of the treatment. At three-month telephone review, the pain had returned to the baseline in 100% (30/30). As the average duration of relief was less than four weeks, diagnostic TPI with LA was not offered to the remaining 74 patients. In a majority of these patients, the response to TPI with LA lasted a few days.
Trigger Point Injection with Steroids
TPI with a mixture of depot steroid and local anesthetic was offered to 104 patients (30 patients who failed TPI with LA and 74 new patients). The mean baseline "worst 24-hour pain" score was 8.3 (SD ¼ 1.47), and the three-month mean follow-up score was 5.7 (SD ¼ 2.78) while the mean change from baseline score at three months was -2.6 (SD ¼2.58). Fifty-four patients responded to steroids at three months while thirty-three patients reported sustained relief for six months (durable responders). The durable responders received repeat TPIs with steroids at six month intervals. Nine patients were lost to follow-up ( Figure 3 ).
Pulsed Radiofrequency Treatment
Seven patients were not offered pulsed radiofrequency treatment. PRF was avoided if the patient had a pacemaker in situ, reported a significant flare-up following TPI with steroids, if the patient had pain elsewhere in the body, trigger points were present in more than two quadrants, and on patient refusal. Forty-three patients received PRF to the myofascial triggers. Twenty-six patients (60%) reported sustained benefit lasting more than six months (durable responders).
Visceral Inflammation
A previous history of visceral inflammation was observed in 78% of patients who underwent trigger point treatment (Table 1) . Surgical trauma on a background of visceral inflammation was noted in 48 patients diagnosed with AMPS. Pain elsewhere in the body (migraine, fibromyalgia, and low back pain) was present in 21% (22/104). Although they scored high on the HADS and EQ-5D, there were equal numbers of responders and nonresponders to trigger point treatment among this subset.
Medical Psychology
During the initial months, all patients with pretreatment abnormal HADS scores were referred for medical psychology. Feedback from the clinical psychologists indicated that patients who received effective trigger point treatment no longer reported low mood and were discharged without any intervention. Thereafter, patients who continued to register abnormal scores on the HADS questionnaire following effective trigger point treatment were subsequently referred for medical psychology. Fifty-three patients registered abnormal scores on HADS prior to trigger point treatment. A third of these patients registered normal HADS scores following successful trigger point treatment. The rest were referred for medical psychology.
Other Outcomes
Patient satisfaction with the AMPS management pathway was high. Sixty-eight (66%) AMPS patients reported that they could remain in gainful employment as a result of effective management of their abdominal pain. Quality of life (EQ-5 D) scores are reported based on the Pareto Classification of Health Change (PCHC) [23] . PCHC classifies change in health following an intervention into four categories: health is better, same, worse, or mixed (better in one dimension, worse in another dimension). There was significant improvement reported in anxiety and depression scores following the interventional management of AMPS (Table 2) . Complications recorded during the three-year audit period included steroid-induced (cataract ¼ 1, weight gain ¼ 12, transient nightmares ¼ 2, postprocedural flare up in pain lasting >1 week ¼ 14) and PRF-related complications (flare-up lasting >1 week ¼ 9).
Discussion
Abdominal myofascial pain syndrome is a well-recognized category of chronic abdominal wall pain. However, the pathophysiology and management of abdominal
Total AMPS audited = 120
Local anestheƟc = 30
Lost to follow up = 9
Steroid ( myofascial pain syndrome appear to be ambiguous in the current literature. Most reports on CWAP focus on anterior cutaneous nerve entrapment (ACNES), and there is a perception that ACNES is the commonest cause of CWAP [15, [24] [25] [26] . In this audit, ACNES was diagnosed in 12% (18/153) of patients presenting with chronic abdominal pain.
Although the concept of viscerosomatic convergance is well established, the significance of viscerosomatic convergance (VSC) in the pathogenesis of AMPS is sparsely reported. As a result, patients with a history of an underlying visceral inflammation presenting with chronic abdominal pain continue to receive visceral pain management, which appears to be largely dependent on escalating opioid therapy [5, 27] .
The author presents a prospective audit into a structured pathway in the management of AMPS. The primary objective was to identify the optimal treatment for the individual patient diagnosed with AMPS. The commonly practiced treatment of trigger point injection with local anesthetics was useful in diagnosing AMPS. However, it was ineffective in providing a durable therapeutic benefit. Similarly, acupuncture was ineffective in providing sustained relief in patients with AMPS secondary to VSC. This is contrast to the efficacy of both TPI with LA and acupuncture for cervicothoracic myofascial pain, where the underlying pathology appears to be repetitive stress. In this series, 72% of patients with AMPS had an underlying history of visceral inflammation.
Patients with AMPS complain of a constant dull localized pain with intermittent sharp flare-ups that can significantly affect function, often resulting in hospital visits and recurrent admissions [5] . During the flare-up, the pain can be referred to the flank, back, groin, or leg. Initial diagnosis is by eliciting a positive Carnett's sign [5, 25] . The diagnosis can be confirmed on having a positive response to trigger point injection [25, 28] . The author recommends that this procedure should be performed under ultrasound guidance as this may enhance both the safety and efficacy of the procedure [5, 25] . Myofascial twitch elicited on insertion of the needle into the muscle containing the trigger point is considered pathognomonic of myofascial pain and can be visualized on ultrasound imaging. Muscle twitch was observed in a third of the patients in this audit. The previously described "needle sign" (patient response when the needle enters the affected area in the muscle) was reliable in identifying the trigger [16] .
Each trigger point was identified by palpation of the tender point and marking the overlying skin, followed by ultrasound scanning of the underlying muscle, and the final confirmation was the elicitation of the needle sign. Each trigger thus identified was treated. It is interesting to note that patients do not complain of pain while the needle traverses the normal muscle. Based on the location of the trigger in the rectus abdominis muscle, the muscle was divided into three zones (Zones 1-3) (Figure 4) .
Zone 4 includes the medial third of the three muscles constituting the lateral abdominal wall (external and internal oblique, transversus abdominis).
Zone 5 includes the lateral third of internal oblique, transversus abdominis, and quadratus lumborum muscle. It was possible to localize the triggers in the zones based on the underlying visceral inflammation (Table 3) .
Abdominal pain as a result of visceral inflammation appears to follow three stages. Stage 1: The first stage is during the acute visceral inflammation, where the sole pain generator is the visceral organ (acute visceral abdominal pain). The pain is diffuse, felt predominantly in the midline, and is associated with autonomic symptoms [29] [30] [31] .
Stage 2: The second stage results from viscerosomatic convergance. VSC describes the convergence of somatic and visceral inputs onto the central nervous system neurons. Acute visceral inflammation results in a massive barrage of afferent visceral signals to the convergent viscero-somatic neurons in the spinal cord. This results in the process of central sensitization that presents as referred muscle pain and hyperalgesia [6, 7, [9] [10] [11] [31] [32] [33] [34] . The pain is more localized, and examination may reveal trigger points in the abdominal musculature (positive Carnett's sign). However, in the presence of active inflammatory markers or ongoing triggers (alcohol in alcohol-induced pancreatitis), the predominant pain generator is visceral and treatment should be directed at controlling visceral inflammation and visceral pain management. Strategies at controlling specific visceral inflammation include proton pump inhibitor (PPI) treatment for esophagitis and gastritis, alcohol cessation and pancreatic duct stenting in chronic pancreatitis, and hormone therapy in endometriosis, to name a few.
Stage 3: The third stage occurs when the underlying visceral inflammation subsides and the principal pain generator moves from the viscera to the overlying abdominal wall as a result of peripheral sensitization (abdominal myofascial pain syndrome). Examples include flank pain in patients with renal colic, upper abdominal pain in chronic pancreatitis, right upper abdominal quadrant muscle tenderness in biliary colic, and lower abdominal pain in women with endometriosis or severe dysmenorrhea [14, [32] [33] [34] [35] [36] [37] . Stratton et al. [38] have also noted the development of long-term remodeling of the central nervous system that presents as myofascial dysfunction (myofascial trigger points) long after endometriosis lesions have been treated. However, the evidence for this phenomenon (Stage 3) is currently limited. The initial barrage of afferent visceral input appears to result in sensitization of nociceptors in the abdominal muscle leading to sustained muscle contraction [6, 7, 9, [32] [33] [34] . It is possible that the central sensitization may biochemically evoke alteration in the muscle as well as enhance peripheral nociceptive activity via antidromic mechanisms, causing changes in the peripheral tissues that persist long after the primary visceral inflammation has ceased [33, 39] . Evidence of trophic changes in the affected muscle has also been reported [10] . Surgery in the presence of VSC may aggravate or reveal underlying AMPS [40] . In this stage, strategies that were effective for visceral pain (opioids, sympathetic nerve blocks) fail, and the treatment should be targeted at the myofascial component (trigger point treatment).
There is an ongoing debate on the existence of myofascial pain syndrome. Recently, Quintner et al. [41] hypothesized that myofascial pain is the result of primary neurogenic inflammation. Dommerholt and Gerwin rebutted their argument [42] . Primary neurogenic inflammation of the anterior cutaneous nerve within the abdominal wall usually presents with cutaneous hypersensitivity (hyperalgesia, allodynia) or hypoesthesia.
In this series, patients with active visceral inflammation (pancreatitis, endometriosis, cystitis) showed features of cutaneous hypersensitivity (allodynia), as well as a positive Carnett's sign (Stage 1 or Stage 2). This implies that primary neurogenic inflammation of the anterior cutaneous nerve may accompany active visceral inflammation. However, none of the patients with AMPS (Stage 3) in this series showed features of allodynia or hypoesthesia. It is possible that there is dysfunction of neural and myofascial elements within the abdominal wall during the various phases of visceral inflammation. At some stage, myofascial dysfunction appears to become predominant, as revealed by the clinical presentation and response to trigger point treatment. However, the current evidence is insufficient to rule out an ongoing neural dysfunction in patients with AMPS. A transient response to TPI with local anesthetic (LA), a durable response to pulsed radiofrequency treatment, and the absence of a local twitch response in a majority of patients suggest the coexistence of neural pathology in AMPS.
Failure to diagnose chronic abdominal wall pain including AMPS and ACNES comes at a significant cost [4, 15] . These patients have undergone clinical, endoscopic, and imaging investigations with negative results, leading to frustration for both the patient and the clinician. Additional testing and investigations increase costs and patient morbidity and come with added risks [1, 43] . AMPS should be actively sought in patients presenting with chronic abdominal pain who have a past history of visceral inflammation. In this audit, Carnett's sign was positive in all patients, including patients with ACNES, AMPS, and patients with ongoing chronic visceral inflammation (Stage 2). A positive Carnett's sign suggests involvement of the abdominal wall in pain generation and cannot be used as a standalone diagnostic sign [44] . Trigger point injection with steroids is both diagnostic and therapeutic in ACNES and AMPS. Response to TPI with steroids can provide valuable information in differentiating between Stage 2 and Stage 3 of viscerosomatic convergance, thereby identifying the appropriate management pathway for patients presenting with chronic abdominal pain with a history of visceral inflammation.
In the author's experience, medical management of AMPS is insufficient and trigger point treatment is necessary to confirm diagnosis and improve function. In this audit, patients reported improvement in pain intensity and mood. Adequate treatment of AMPS has been shown to reduce opioid consumption, length of hospital stay, and recurrent hospital admission and could result in cost savings [5] . Patient satisfaction with the AMPS management pathway was high. The author recommends trialing a diagnostic TPI with steroids in patients presenting with chronic abdominal pain as the benefits of confirming the right diagnosis far outweigh the limited therapeutic benefit of the procedure in this group of often-desperate patients. One-fifth of the patients in this series failed to respond to trigger point intervention.
Factors predicating poor response include prolonged flare-up following trigger point treatment, severe generalized anxiety disorder, pain elsewhere in the body, and poorly controlled gastro-esophageal reflux disease (GORD) with or without biliary gastritis.
Limitations include an open-label, nonrandomized observational design in a limited cohort of patients under the care of a single physician. The decision to exclude TPI with LA in the management pathway was based on the observation in a cohort of 30 patients. It is possible that repeat TPI with LA may have resulted in a prolonged response. Evidence-based medicine (EBM) has an important role in establishing treatment standards. The author is aware that this report ranks low on the EBM scale. However, tailoring treatment for the individual patient should remain a priority, especially in pain medicine, and here, practice-based evidence such as that reported herein could have some significance.
This work offers additional support for peripherally maintained mechanisms for viscerosomatic convergance in AMPS. Further work is required to identify more specific mechanisms and interventions to target them in the management of AMPS.
